Retatrutide 20
A triple GLP-1 / GIP / glucagon agonist in a pre-filled 3 mL click pen. The 20 mg pen for metabolic research.Each click delivers67 µgfrom a 3 mL · 300-click pen.
Featured in these stacks: Summer Stack.
how many clicks
for your dose?
ThisRetatrutide 20pen holds20 mgacross 300 clicks, so each click delivers67 µg. Tap a dose or turn the dial; we'll count the clicks. For research reference only.
why109researchers chose this pen
chose it for the click dosing, no syringes, no unit maths.
verified purity, checked against the public COA before first use.
precise clicks in every 3 mL pen, the whole protocol in one barrel.
re-order or refer a colleague within three months.
about the
Retatrutide 20pen
Retatrutide is an investigational triple incretin receptor agonist, supplied in a pre-filled 3 mL / 300-click pen for in-vitro research. Each batch is independently assayed.
"Counted my clicks, done in ten seconds. No syringes, no unit maths, the dosing card lives on my desk now."
"Checked the batch number against the public COA before first use, matched to the decimal. That's why I switched."
"Arrived cold, packed like something precious. Temperature strip still green on arrival. Genuinely impressed."
why a pen beats
a vial & syringe
Traditional research peptides arrive as lyophilised powder that must be reconstituted, drawn into insulin syringes, and converted from milligrams to units by hand, every step a chance for a dosing error.
A multi-dose pen removes the whole failure chain. The peptide arrivesalready dissolved and calibrated. Attach a fresh needle, turn the dial until you count your clicks, and you're done, the same audible-click mechanism trusted in insulin and GLP-1 pens worldwide.
Pens travel and store better, too: no open vials, no bent needles, no septum contamination after repeated draws. One sealed barrel, ten sterile needles, one dosing card.
how to buy
peptides safely
The peptide market has a purity problem: independent surveys routinely find underdosed, mislabelled or contaminated product sold online. The only reliable defence isthird-party verification you can check yourself, not a supplier's own claims.
Before buying any peptide pen, ask three questions. Is every batch tested by an independent lab? Is the certificate of analysis available, so you can check your exact lot before first use? And does it ship cold-chain, insulated and gel-packed, so what was tested is what arrives?
Veyvora answers yes on every order, independent assay, a COA on request against the batch number, and cold dispatch within 24 hours, paperwork packed inside.
pairs well with
view all
Purchase Retatrutide 20 mg Pen | 2026
Veyvora’s Retatrutide 20 mg Pen is a pre-filled 3 mL, 300-click research-format pen containing LY3437943, an investigational triple receptor agonist of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon pathways, supplied strictly for in-vitro laboratory research use only. At 20 mg across 300 clicks, each click delivers approximately 67 µg. No Medicines and Healthcare products Regulatory Agency (MHRA) or European Medicines Agency (EMA) marketing authorisation for a retatrutide 20 mg pen appears on the public registers as of 2026; verify current status on the MHRA product register before procurement.
| Specification | Detail |
|---|---|
| Active compound | Retatrutide (LY3437943) |
| Total content | 20 mg |
| Fill volume | 3 mL |
| Click count | 300 |
| Dose per click | ≈ 67 µg |
| Intended use | In-vitro laboratory research only |
Price: No NHS list price, British National Formulary (BNF) entry, or licensed-wholesaler tariff exists for this presentation. Any merchant price is a commercial offer, not a regulated figure, and is not reproduced here as a purchase fact.
Availability and purchase path: No authorised UK pharmacy or licensed-wholesaler stock-keeping unit (SKU) exists for a retatrutide 20 mg pen, because retatrutide has no UK marketing authorisation and is supplied here for in-vitro laboratory research only, not as a medicine. The research-procurement route is to request the batch-specific certificate of analysis from Veyvora, verify it against the pen’s batch number, then order the pen for laboratory use.
Purchase Retatrutide 20 mg Pen: Product Identity and Scope
Veyvora’s Retatrutide 20 mg Pen is a pre-filled 3 mL, 300-click research-format pen containing LY3437943, an investigational triple receptor agonist of GLP-1, GIP, and glucagon pathways, supplied strictly for in-vitro laboratory research use only. Each click delivers approximately 67 µg from the 20 mg total. No MHRA or EMA marketing authorisation for a retatrutide 20 mg pen appears on the public registers as of 2026; verify current status on the MHRA product register before procurement.
| Specification | Detail |
|---|---|
| Active compound | Retatrutide (LY3437943) |
| Total content | 20 mg |
| Fill volume | 3 mL |
| Click count | 300 |
| Dose per click | ≈ 67 µg |
| Intended use | In-vitro laboratory research only |
Online listings for a retatrutide 20 mg pen are not equivalent to a UK-authorised injectable and must not be treated as such. Supplying or advertising an unlicensed medicine for human use in Great Britain is restricted under the Human Medicines Regulations 2012 [1]. Before first use, verify your batch against its certificate of analysis (CoA) to confirm the pen and batch number match the public certificate.
Verified Specifications
Veyvora’s Retatrutide 20 mg Pen is specified as a pre-filled 3 mL pen containing 20 mg of retatrutide (LY3437943) across 300 clicks, yielding approximately 67 µg per click. That figure comes from the supplier’s own product data, not from a regulator-approved Summary of Product Characteristics (SmPC) or device specification. No MHRA- or EMA-authorised SmPC for a retatrutide 20 mg dosing pen exists on the public registers as of 2026; all click-count and dose-per-click values below reflect Veyvora’s stated specification only.
| Specification | Veyvora-stated value | Independent verification |
|---|---|---|
| Active compound | Retatrutide (LY3437943) | No MHRA/EMA SmPC available (2026) |
| Total content | 20 mg | Confirm against batch CoA |
| Fill volume | 3 mL | Confirm against batch CoA |
| Click count | 300 | Supplier-stated; no regulator-settled figure |
| Dose per click | ≈ 67 µg | Arithmetic from 20 mg ÷ 300 clicks |
| Needle compatibility | Confirm with operator | No authorised device specification available |
| Intended use | In-vitro laboratory research only | No authorised device specification available |
Phase 2 clinical work on retatrutide described weekly subcutaneous administration of the investigational compound, not a commercial multi-dose pen with a published click-to-mg mapping (Jastreboff et al., NEJM, 2023). The click arithmetic above is a supplier presentation, not a figure validated against trial-grade formulation data.
For storage conditions that apply to this format, see Retatrutide storage and stability guidance. For mechanism and published-evidence context, the Retatrutide research profile covers the compound’s receptor pharmacology without conflating it with this pen’s commercial specification.
Batch Documentation and Analytical Evidence
Each retatrutide pen ships with an independent, batch-specific certificate of analysis (CoA) reporting LC-MS identity, HPLC purity (≥ 98.0%), peptide content (95–105%) and a safety panel, so the material is characterised before any research use. Veyvora states that each batch is verified independently by Asterion Analytics, then again by Veyvora’s own internal testing, using high-performance liquid chromatography (HPLC), mass spectrometry, and endotoxin assay, with the CoA matched to the batch number before first use (Veyvora quality documentation, 2026). A CoA is an analytical record rather than Good Manufacturing Practice (GMP) batch release or an MHRA marketing authorisation; match the batch number on the pen to the published certificate before use.
Before placing an order, confirm that the CoA on the live product page carries the exact batch number of the pen being dispatched, names the analytical method and laboratory, and states the result against a defined acceptance criterion, not a generic document applied across multiple lots.
What a CoA Can and Cannot Prove
Primary analytical methods such as HPLC and mass spectrometry characterise the tested aliquot; they do not guarantee that every subsequent pen from the same listing matches that result. Endotoxin assay data applies to the sample submitted, under the conditions of that test run. Confirm that the certificate is tied to the specific batch number on the pen and that it names the analytical method, laboratory and the acceptance criterion applied.
Receptor-Pharmacology Context
For compound-level context that sits outside this transactional page, the Retatrutide versus Tirzepatide comparison addresses receptor-pharmacology differences without conflating them with batch-quality claims.
Handling and Storage
No MHRA-approved storage specification exists for a retatrutide 20 mg pen, because retatrutide holds no UK marketing authorisation as of 2026. Veyvora states that orders are dispatched cold in an insulated bag with a gel ice pack (Veyvora cold-chain specification, 2026); this is a supplier-stated handling policy, not a regulator-settled cold-chain requirement.
What Cannot Be Confirmed Without Primary Documentation
In-use shelf life, freeze-thaw cycle limits, and pen-in-use periods are not values this page can supply without a current, batch-specific primary document from the supplier. Before first use, confirm these figures directly against the live product label or structured data sheet for the specific batch being received. Where those values are absent from the documentation, treat them as unconfirmed and contact the supplier before proceeding.
Peptide solutions are temperature-sensitive as a class, but applying a generic stability assumption to a specific unlicensed pen is not a substitute for batch-level data. To match your pen’s storage conditions to its documented analytical results, verify your batch against its CoA before opening the packaging.
Ordering Information
No authorised UK pharmacy, NHS listing, or licensed-wholesaler SKU exists for a retatrutide 20 mg pen as of 2026. Supplying or advertising an unlicensed medicine for human use in Great Britain is restricted under the Human Medicines Regulations 2012 [1]; this page does not provide checkout steps, pre-order codes, or distributor onboarding routes.
What Cannot Be Confirmed Here
GBP price, current stock level, and delivery timescales are not values this page can verify from a regulator or licence-holder source. Any cart price from a research-chemical supplier is a merchant offer, not a regulated or independently confirmed figure, and is omitted accordingly.
Research procurement route
Veyvora supplies the retatrutide 20 mg pen for in-vitro laboratory research only; it is not sold as a medicine and is not for human use. To procure, request the batch-specific certificate of analysis, verify it against the pen’s batch number, then order the pen for laboratory use. For Veyvora’s documented cold-chain packaging and in-vitro supply terms, the Retatrutide storage and stability guidance covers the supplier’s stated 2–8 °C dispatch policy.
Research-Use-Only Limitations
A “research use only” (RUO) label does not authorise human administration, patient compounding, or wholesale distribution of retatrutide as a medicine in the United Kingdom. Under the Human Medicines Regulations 2012, a product is regulated by its presentation and intended use, not by a supplier’s footer disclaimer [1]. Procuring a retatrutide 20 mg pen for in-vitro laboratory work remains the buyer’s responsibility to verify as lawful; placing the same material on the market as a medicine, or supplying it to a clinic, falls outside any RUO exemption.
What RUO Does Not Cover
Prospective distributors cannot treat RUO pens as parallel-trade stock or as a licensed-equivalent supply route. For any procurement audit trail, match each pen’s batch number to its published certificate of analysis and retain the certificate as the analytical record for that lot.
Researchers exploring related research pens can review Veyvora’s verified research-peptide catalogue for other in-vitro supply options.
Related Research and Comparison Pages
The citable efficacy and safety context for retatrutide (LY3437943) sits in the peer-reviewed trial literature, not in merchant comparison tables. Jastreboff et al., published in the New England Journal of Medicine on 26 June 2023, is the Phase 2 obesity reference; ongoing Phase 3 work is registered under Lilly’s TRIUMPH programme on ClinicalTrials.gov, with records spanning 2024–2026 [2]. Confirm NCT numbers directly on the live register before citing them, as trial status changes.
Before placing any order, verify your batch against its CoA by matching the batch number on your retatrutide pen to the public certificate of analysis. Where the certificate lists an HPLC purity figure, reading what HPLC purity does and does not prove first is advisable: assay purity is a statement about the tested aliquot, not a guarantee of identity, sterility, or suitability for any specific in-vitro protocol.
Sources
[1] legislation.gov.uk, https://www.legislation.gov.uk/uksi/2012/1916 [2] ICTRP Search Portal, pmc.ncbi.nlm.nih.gov, https://pmc.ncbi.nlm.nih.gov/articles/PMC11445313/
